» Articles » PMID: 37800635

Body Mass Index and Waist Circumference in Relation to Risk of Recurrence and Progression After Non-muscle Invasive Bladder Cancer

Overview
Journal Cancer Med
Specialty Oncology
Date 2023 Oct 6
PMID 37800635
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Obesity may be associated with increased risk of recurrence and progression in patients with non-muscle invasive bladder cancer (NMIBC), but evidence is limited and inconsistent. We examined the associations of body mass index (BMI), waist circumference, and waist-to-hip ratio (WHR) with risk of recurrence and progression among patients with NMIBC.

Methods: This prospective study included 1029 patients diagnosed with primary NMIBC between 2014 and 2017. Patients reported weight 2 years before diagnosis at baseline, and weight, waist and hip circumference at 3 months postdiagnosis. Associations were quantified using Cox proportional hazard analyses, adjusted for clinical and lifestyle characteristics.

Results: More than half of patients were overweight (49%) or obese (19%) after diagnosis. During a median follow-up time of 3.6 years, 371 patients developed ≥1 recurrence and 53 experienced progression. No associations with recurrence were observed for BMI (HR 0.94; 95% CI 0.82, 1.07), waist circumference (HR 0.95; 95% CI 0.86, 1.05), or WHR (HR 0.90; 95% CI 0.76, 1.06). In contrast, higher BMI was associated with a 40% increased risk of progression, with only the 2-year prediagnosis association reaching statistical significance (HR 1.42; 95% CI 1.09, 1.84). No associations for pre-to-postdiagnosis weight change were found.

Conclusion: General and abdominal obesity were not associated with recurrence risk among patients with NMIBC, but might be associated with increased risk of progression. Studies with sufficient sample size to stratify by tumor stage and treatment are needed to better understand whether and how obesity could influence prognosis.

Citing Articles

Circulating levels of cytokines and risk of urologic cancers: a two-sample Mendelian randomization study.

Song J, Sun X, Wang T, Li C, Yuan L BMC Cancer. 2024; 24(1):1261.

PMID: 39390542 PMC: 11465925. DOI: 10.1186/s12885-024-13016-9.


Charlson-Deyo Comorbidity Index as a Novel Predictor for Recurrence in Non-Muscle-Invasive Bladder Cancer.

Scheipner L, Zurl H, Altziebler J, Pichler G, Schopfer-Schwab S, Jasarevic S Cancers (Basel). 2023; 15(24).

PMID: 38136315 PMC: 10742244. DOI: 10.3390/cancers15245770.


Body mass index and waist circumference in relation to risk of recurrence and progression after non-muscle invasive bladder cancer.

van Zutphen M, Beeren I, Aben K, van der Heijden A, Witjes J, Kiemeney L Cancer Med. 2023; 12(20):20459-20469.

PMID: 37800635 PMC: 10652337. DOI: 10.1002/cam4.6620.

References
1.
Babjuk M, Burger M, Comperat E, Gontero P, Mostafid A, Palou J . European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019; 76(5):639-657. DOI: 10.1016/j.eururo.2019.08.016. View

2.
Nicolaou M, Gademan M, Snijder M, Engelbert R, Dijkshoorn H, Terwee C . Validation of the SQUASH Physical Activity Questionnaire in a Multi-Ethnic Population: The HELIUS Study. PLoS One. 2016; 11(8):e0161066. PMC: 5004804. DOI: 10.1371/journal.pone.0161066. View

3.
de Hollander E, Zwart L, de Vries S, Wendel-Vos W . The SQUASH was a more valid tool than the OBiN for categorizing adults according to the Dutch physical activity and the combined guideline. J Clin Epidemiol. 2011; 65(1):73-81. DOI: 10.1016/j.jclinepi.2011.05.005. View

4.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

5.
White I, Royston P . Imputing missing covariate values for the Cox model. Stat Med. 2009; 28(15):1982-98. PMC: 2998703. DOI: 10.1002/sim.3618. View